Author

E. Chendamarai

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Assay:proteomics· 1

Frequent Co-Authors

J. F. DiPersio· 2 shared M. P. Rettig· 2 shared A. A. Alex· 1 shared A. A. Desai· 1 shared A. Asnani· 1 shared A. Diab· 1 shared A. Diwan· 1 shared A. Girardi· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

J. F. DiPersio

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Streptavidin-drug conjugates streamline optimization of antibody-based conditioning for hematopoietic stem cell transplantation

A. R. Yelamali, E. Chendamarai, J. K. Ritchey, M. P. Rettig, J. F. DiPersio, S. P. Persaud

This paper develops a streptavidin-drug conjugate platform to efficiently optimize antibody-based conditioning for HSCT, finding that PBD dimer SGD-1882 is most effective for targeting HSCs and AML cells.

bioRxiv · Feb 12, 2024Immunology

Apolipoprotein M attenuates anthracycline cardiotoxicity and lysosomal injury

Z. Guo, C. Valenzuela Ripoll, A. Picataggi, D. R. Rawnsley, M. Ozcan, J. A. Chirinos, E. Chendamarai, A. Girardi, T. Riehl, H. Evie, A. Diab, A. Kovacs, K. Hyrc, X. Ma, A. Asnani, , A. Javaheri

This paper investigates the role of apolipoprotein M in anthracycline cardiotoxicity, finding that ApoM protects against cardiac dysfunction and lysosomal injury through the autophagy-lysosome pathway.

bioRxiv · Jan 12, 2021Pharmacology & Toxicology

Arsenic trioxide resistance in acute promyelocytic leukemia: More to it than PML mutations

N. Balasundaram, S. Ganesan, E. Chendamarai, H. K. Palani, A. Venkatraman, A. A. Alex, S. David, S. Krishna, A. Korula, N. B. Janet, P. Balasubramanian, V. Mathews

This study identifies metabolic rewiring as a mechanism of arsenic trioxide resistance in APL and shows that combining ATO with mitocans can overcome resistance.

bioRxiv · Jun 21, 2020 · PreprintCancer Biology